semaglutide april 22 2025 FDA's Removal of and the Evolving Tirzepatide Decisions: What Compounders Need to Know Semaglutide Shortage Ends: Compounded Versions

PlexusDx provides personalized dosing and optional genetic testing to optimize your specific response profile

Some plans might cover it, others wont

All medications come from licensed 503A compounding pharmacies, PlexusDx serves all 50 states without requiring insurance or membership, and HSA/FSA accounts are eligible

US Holds Largest Share in North America Driven by High Healthcare Spending The US GLP-1 receptor agonist market held the largest share in North America in 2025 due to its patient population, favorable regulatory environment, and high healthcare spending per capita

However, Tirzepatide is showing promising results in clinical trials and has started the conversation of whats next